CV8，一种由双氢青蒿素、哌喹、甲氧苄啶和伯氨喹组成的新组合，与阿托伐醌-氯胍在越南治疗恶性疟的疗效比较。

CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam.

作者信息

Giao Phan T, de Vries Peter J, Hung Le Q, Binh Tran Q, Nam Nguyen V, Kager Piet A

机构信息

Division of Infectious Diseases, Tropical Medicine & AIDS, Academic Medical Center, Amsterdam, The Netherlands.

出版信息

Trop Med Int Health. 2004 Feb;9(2):209-16. doi: 10.1046/j.1365-3156.2003.01180.x.

DOI:10.1046/j.1365-3156.2003.01180.x

PMID:15040557

Abstract

OBJECTIVES

To study a new combination, based on dihydroartemisinin and piperaquine (CV8) and atovaquone/proguanil (Malarone) for treatment of uncomplicated falciparum malaria in Vietnam.

METHODS

Vietnamese adults with falciparum malaria were allocated randomly to treatment with dihydroartemisinin/piperaquine/trimethoprim/primaquine 256/2560/720/40 mg (CV8, n = 84) or Malarone 3000/1200 mg (n = 81), both over 3 days. Patients were followed-up for 28 days.

RESULTS

All patients recovered rapidly. The mean (95% CI) parasite elimination half-life of CV8 was 6.8 h (6.2-7.4) and of Malarone 6.5 h (6.1-6.9) (P = 0.4). Complete parasite clearance time was 35 (31-39) and 34 h (31-38) (P = 0.9). The 28-day cure rate was 94% and 95%, respectively (odds ratio 0.84, 95% CI 0.18-3.81). No significant side-effects were found.

CONCLUSION

CV8 and Malarone are effective combinations against multi-drug resistant falciparum malaria. CV8 has the advantage of a low price.

摘要

目的

研究一种基于双氢青蒿素和哌喹（CV8）以及阿托伐醌/氯胍（malarone）的新组合，用于治疗越南非复杂性恶性疟。

方法

将患有恶性疟的越南成年人随机分配接受双氢青蒿素/哌喹/甲氧苄啶/伯氨喹256/2560/720/40毫克（CV8，n = 84）或malarone 3000/1200毫克（n = 81）治疗，疗程均为3天。对患者进行28天的随访。

结果

所有患者均迅速康复。CV8的平均（95%CI）寄生虫清除半衰期为6.8小时（6.2 - 7.4），malarone为6.5小时（6.1 - 6.9）（P = 0.4）。完全寄生虫清除时间分别为35（31 - 39）小时和34小时（31 - 38）（P = 0.9）。28天治愈率分别为94%和95%（优势比0.84，95%CI 0.18 - 3.81）。未发现明显副作用。